Investigation of in vivo activated T cells in multiple sclerosis and inflammatory central nervous system diseases

Plasminogen activation in multiple scler

Plasminogen activation in multiple sclerosis and other central nervous system diseases

✍ F.O.T. Akenami; M. Koskiniemi; V. Sirén; S. Mustjoki; M. Färkkilä; A. Vaheri 📂 Article 📅 1998 🏛 Elsevier Science 🌐 English ⚖ 141 KB

Specific central nervous system recruitm

Specific central nervous system recruitment of HLA-G+ regulatory T cells in multiple sclerosis

✍ Yu-Hwa Huang; Alla L. Zozulya; Christian Weidenfeller; Imke Metz; Dorothea Buck; 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 510 KB

## Abstract ## Objective We have recently described a novel population of natural regulatory T cells (T~reg~) that are characterized by the expression of HLA‐G and may be found at sites of tissue inflammation (HLA‐G^pos^ T~reg~). Here we studied the role of these cells in multiple sclerosis (MS),

Diagnostic significance of IgG-synthesiz

Diagnostic significance of IgG-synthesizing activated B cells in acute inflammatory diseases of the central nervous system

✍ Schädlich, H. -J. ;Felgenhauer, K. 📂 Article 📅 1985 🏛 Springer-Verlag 🌐 English ⚖ 575 KB

[Current Topics in Microbiology and Immu

[Current Topics in Microbiology and Immunology] Advances in multiple Sclerosis and Experimental Demyelinating Diseases Volume 318 || The Multiple Sclerosis Degradome: Enzymatic Cascades in Development and Progression of Central Nervous System Inflammatory Disease

✍ Scarisbrick, I. A. (author) 📂 Article 📅 2008 🏛 Springer Berlin Heidelberg 🌐 German ⚖ 230 KB

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people

[Current Topics in Microbiology and Immu

[Current Topics in Microbiology and Immunology] Advances in multiple Sclerosis and Experimental Demyelinating Diseases Volume 318 || The Multiple Sclerosis Degradome: Enzymatic Cascades in Development and Progression of Central Nervous System Inflammatory Disease

✍ Scarisbrick, I. A. (author) 📂 Article 📅 2008 🏛 Springer Berlin Heidelberg 🌐 German ⚖ 230 KB

Controversy still exists regarding how early disease-modifying agents (DMA) should be commenced and whether all patients with relapsing-remitting MS should in fact be treated. To answer these questions, it is also important to know the natural history of the disease. MS affects nearly 400,000 people

Progress in understanding inflammatory a

Progress in understanding inflammatory and autoimmune diseases of the central nervous system

✍ Reinhard Hohlfeld; Ludwig Kappos 📂 Article 📅 2009 🏛 Springer-Verlag 🌐 English ⚖ 47 KB